Tumor Bio-distribution
Tumor Bio-distribution - Related Videos
13:29
Biodistribution of Nano-drug Carriers: Applications of SEM
0 Views •
2023
Source: Peiman Shahbeigi-Roodposhti and Sina Shahbazmohamadi, Biomedical Engineering Department, University of Connecticut, Storrs, Connecticut Nanoparticles have been increasingly used research towards targeted drug delivery and controlled drug release. While most of these particles have been developed as polymeric or liposomal particles because of their biocompatibility, there is a trend in current research toward the use of metallic and magnetic nanoparticles. These metallic nanoparticles...
06:15
An In Vivo Immunofluorescence Localization Method to Study Antibody Biodistribution
0 Views •
2025
This video demonstrates an in vivo immunofluorescence localization (IVIL) technique to study the biodistribution of tumor-targeting antibodies in a murine model of breast cancer. Upon the intravenous injection of a tumor-specific antibody in the mouse, the tumor is surgically isolated, and the localization of the antibody within the tumor tissue is confirmed via ex vivo immunostaining.
14:04
Viral Nanoparticles for In vivo Tumor Imaging
0 Views •
Cited by 45 •
2012
Plant viral nanoparticles (VNPs) are promising platforms for applications in biomedicine. Here, we describe the procedures for plant VNP propagation, purification, characterization, and bioconjugation. Finally, we show the application of VNPs for tumor homing and imaging using a mouse xenograft model and fluorescence imaging.
13:35
Acute and Chronic Models of Hyperglycemia in Zebrafish: A Method to Assess the Impact of Hyperglycemia on Neurogenesis and the Biodistribution of Radiolabeled Molecules
0 Views •
Cited by 25 •
2017
This work describes methods to establish acute and chronic hyperglycemia models in zebrafish. The aim is to investigate the impact of hyperglycemia on physiological processes, such as constitutive and injury-induced neurogenesis. The work also highlights the use of zebrafish to follow radiolabeled molecules (here, [18F]-FDG) using PET/CT.
08:53
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
0 Views •
Cited by 1 •
2019
The in vivo immunofluorescence localization (IVIL) method can be used to examine in vivo biodistribution of antibodies and antibody conjugates for oncological purposes in living organisms using a combination of in vivo tumor targeting and ex vivo immunostaining methods.
FAQs
Tumor bio-distribution reflects a sequence of transport events rather than simple delivery to the tumor. An agent must move through the circulation, cross tumor vessels when permeability allows, travel through interstitial space, and potentially enter or remain within cells. These steps determine local tissue exposure and retention, which indicate whether the intended target receives a meaningful amount of the agent.
Blood flow, vascular permeability, interstitial transport, cellular uptake, and clearance collectively shape exposure patterns. Differences in these processes can cause an agent to accumulate, remain briefly, or be removed more rapidly from one tissue than another. Examining their combined effects helps explain why administration alone does not guarantee sustained tumor exposure or limited distribution to normal tissues.
Initial tumor delivery and subsequent retention provide different information. An agent may reach tumor tissue but leave it quickly, producing limited exposure despite measurable uptake. Retention therefore helps researchers judge how long the agent remains available at the target and whether its distribution pattern supports therapeutic activity, imaging, or further development of the delivery approach.
Researchers assess distribution through imaging, tissue sampling, and quantitative assays. Imaging can track where an agent is located, while tissue sampling permits direct examination of tumor and normal tissues. Quantitative assays add measurements of tissue-associated agent levels. Using these approaches, investigators evaluate exposure, retention, and whether the agent reaches its intended target.
These studies are used when investigators need evidence that a drug, biologic, nanoparticle, or imaging agent reaches the desired tumor site. Results support dose selection, delivery-system design, therapeutic efficacy assessment, and safety evaluation. They are especially relevant when treatment success depends on tissue exposure, because distribution data reveal whether administration produces the intended spatial pattern.
Distribution findings show whether an agent concentrates in tumors, remains there, or also reaches normal tissues. Investigators can use this information to refine delivery-system design and assess whether exposure aligns with the intended target. The same measurements contribute to safety evaluation by identifying distribution patterns that may affect normal tissues, while also informing judgments about therapeutic efficacy.